X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (43562) 43562
Book Review (9220) 9220
Publication (3668) 3668
Book / eBook (682) 682
Book Chapter (191) 191
Conference Proceeding (115) 115
Magazine Article (107) 107
Newspaper Article (69) 69
Newsletter (64) 64
Dissertation (30) 30
Web Resource (10) 10
Government Document (8) 8
Trade Publication Article (7) 7
Data Set (4) 4
Reference (3) 3
Presentation (2) 2
Journal / eJournal (1) 1
Paper (1) 1
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (40414) 40414
humans (30734) 30734
male (20359) 20359
animals (16828) 16828
female (16063) 16063
cardiac & cardiovascular systems (10459) 10459
middle aged (10043) 10043
peripheral vascular disease (9818) 9818
aged (8389) 8389
risk factors (7914) 7914
adult (7004) 7004
rats (6932) 6932
abridged index medicus (6171) 6171
cardiovascular diseases - chemically induced (4847) 4847
mice (4703) 4703
hematology (4459) 4459
disease models, animal (4310) 4310
pharmacology & pharmacy (3915) 3915
time factors (3908) 3908
treatment outcome (3906) 3906
cardiovascular disease (3664) 3664
hypertension (3580) 3580
risk (3351) 3351
cardiovascular diseases (3339) 3339
hemorrhage - chemically induced (3120) 3120
research (3032) 3032
mortality (2967) 2967
analysis (2963) 2963
cardiovascular (2797) 2797
dose-response relationship, drug (2732) 2732
health aspects (2720) 2720
rats, sprague-dawley (2688) 2688
aged, 80 and over (2681) 2681
inflammation (2623) 2623
care and treatment (2591) 2591
cardiology (2587) 2587
oxidative stress (2573) 2573
blood pressure - drug effects (2490) 2490
hypertension - chemically induced (2488) 2488
therapy (2464) 2464
physiology (2445) 2445
risk assessment (2401) 2401
surgery (2400) 2400
expression (2332) 2332
heart (2321) 2321
drug therapy (2292) 2292
cardiovascular system (2291) 2291
anticoagulants - adverse effects (2268) 2268
cancer (2255) 2255
cardiovascular-disease (2226) 2226
disease (2158) 2158
medicine & public health (2147) 2147
atherosclerosis (2143) 2143
article (2125) 2125
retrospective studies (2093) 2093
prevention (2001) 2001
rodents (1989) 1989
physiological aspects (1975) 1975
myocardial-infarction (1930) 1930
medicine, general & internal (1904) 1904
blood pressure (1851) 1851
rats, wistar (1851) 1851
cells, cultured (1849) 1849
diabetes (1849) 1849
vascular endothelial growth factor (1833) 1833
mice, inbred c57bl (1771) 1771
medicine (1764) 1764
prospective studies (1741) 1741
stroke (1732) 1732
cell biology (1697) 1697
adolescent (1669) 1669
angiogenesis (1658) 1658
oncology (1613) 1613
blood-pressure (1598) 1598
respiratory system (1578) 1578
studies (1574) 1574
thrombosis (1574) 1574
endothelium (1566) 1566
proteins (1545) 1545
cardiovascular diseases - prevention & control (1543) 1543
follow-up studies (1540) 1540
electrocardiography (1537) 1537
toxicology (1531) 1531
cells (1512) 1512
incidence (1512) 1512
research article (1442) 1442
complications and side effects (1437) 1437
biochemistry & molecular biology (1432) 1432
drug therapy, combination (1424) 1424
apoptosis (1396) 1396
platelet aggregation inhibitors - adverse effects (1395) 1395
anticoagulants (1379) 1379
activation (1377) 1377
hypertension - physiopathology (1368) 1368
heart failure (1357) 1357
nitric oxide (1342) 1342
gene expression (1340) 1340
inhibition (1317) 1317
anticoagulants - therapeutic use (1294) 1294
endothelium, vascular - drug effects (1279) 1279
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (570) 570
Collection Dvlpm't (Acquisitions) - Closed Orders (25) 25
Collection Dvlpm't (Acquisitions) - Vendor file (20) 20
Earth Sciences (Noranda) - Stacks (12) 12
UTL at Downsview - May be requested (11) 11
UofT at Scarborough - Stacks (11) 11
Online Resources - Online (10) 10
Scarborough Hospital - General (10) 10
Providence Healthcare - Stacks (9) 9
Toronto East General Hospital - Stacks (8) 8
UofT at Mississauga - Stacks (8) 8
Humber River Regional Hospital - Church Stacks (7) 7
St. Michael's Hospital - Stacks (7) 7
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (7) 7
Humber River Regional Hospital - Finch Stacks (6) 6
Scarborough Hospital - Birchmount (6) 6
Lakeridge Health Sciences - Oshawa (5) 5
Trillium Health Centre - Stacks (5) 5
Gerstein Science - Circulation Desk (4) 4
Providence Healthcare - Reference (4) 4
Royal Ontario Museum - Stacks (4) 4
Credit Valley Hospital - Stacks (3) 3
Toronto East General Hospital - Reference (3) 3
West Park Healthcare Centre - Stacks (3) 3
Gerstein Science - Missing (2) 2
Humber River Regional Hospital - Stacks (2) 2
Markham Stouffville Hospital - Stacks (2) 2
Providence Healthcare - Reserve desk (2) 2
St. Michael's College (John M. Kelly) - 2nd Floor (2) 2
Church Stacks (1) 1
Credit Valley Hospital - Online (1) 1
Dentistry (Harry R Abbott) - May be requested in 6-10 wks (1) 1
Earth Sciences (Noranda) - Missing (1) 1
Earth Sciences (Noranda) - Reference (1) 1
Engineering & Comp. Sci. - Stacks (1) 1
Finch Stacks (1) 1
Gerstein Science - May be requested in 6-10 wks (1) 1
Gerstein Science - Reference (1) 1
Law (Bora Laskin) - Stacks (1) 1
Physics - Stacks (1) 1
Robarts - Stacks (1) 1
Scarborough Hospital - Hospital Department (1) 1
St Josephs Health Centre - Reference (1) 1
St. Michael's Hospital - Circulation Desk (1) 1
St. Michael's Hospital - Online (1) 1
Sunnybrook Health Sciences Centre - Holland Stacks (1) 1
Sunnybrook Health Sciences Centre - Online (1) 1
Toronto East General Hospital - Pharmacy (1) 1
UofT at Scarborough - May be requested in 6-10 wks (1) 1
West Park Healthcare Centre - Pharmacy (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (43249) 43249
French (343) 343
German (283) 283
Russian (250) 250
Spanish (141) 141
Polish (89) 89
Italian (80) 80
Dutch (34) 34
Japanese (34) 34
Chinese (28) 28
Hungarian (21) 21
Czech (20) 20
Portuguese (19) 19
Finnish (12) 12
Swedish (11) 11
Norwegian (10) 10
Croatian (9) 9
Danish (9) 9
Hebrew (9) 9
Bulgarian (8) 8
Romanian (8) 8
Turkish (8) 8
Arabic (2) 2
Lithuanian (2) 2
Serbian (2) 2
Romansh (1) 1
Slovak (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cardiovascular toxicology, ISSN 1530-7905, 2001
Journal
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 3, pp. 203 - 212
Adults with vascular disease were treated with a statin to lower LDL cholesterol and were assigned to receive either extended-release niacin plus laropiprant... 
NICOTINIC-ACID | LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | METABOLIC SYNDROME | MYOCARDIAL-INFARCTION | RANDOMIZED-TRIALS | EFFICACY | SAFETY | PLACEBO-CONTROLLED TRIAL | NIACIN/LAROPIPRANT | DYSLIPIDEMIA | Follow-Up Studies | Humans | Middle Aged | Male | Hypercholesterolemia - drug therapy | Indoles - administration & dosage | Infection - chemically induced | Niacin - administration & dosage | Treatment Failure | Musculoskeletal Diseases - chemically induced | Niacin - adverse effects | Cholesterol, LDL - blood | Female | Hypolipidemic Agents - adverse effects | Atherosclerosis - drug therapy | Double-Blind Method | Risk Factors | Indoles - adverse effects | Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use | Hypolipidemic Agents - administration & dosage | Diabetes Mellitus - chemically induced | Aged | Hemorrhage - chemically induced | Delayed-Action Preparations | Drug Combinations | Dose-response relationship (Biochemistry) | Laropiprant | Blood circulation disorders | Care and treatment | Dosage and administration | Niacin | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Stroke | Heart attacks | Risk groups | Diabetes mellitus | Cardiovascular disease | Low density lipoprotein | Cholesterol | Musculoskeletal system | Vascular diseases | Arteriosclerosis | Vitamin B | Skin | Lipoproteins (high density) | Drug dosages | Statins | Index Medicus | Abridged Index Medicus
Journal Article
JAMA, ISSN 0098-7484, 12/2012, Volume 308, Issue 23, pp. 2497 - 2506
CONTEXT An estimated 10% to 20% of patients cannot tolerate statins or adequate doses to achieve treatment goals. Plasma proprotein convertase subtilisin/kexin... 
LDL CHOLESTEROL | MEDICINE, GENERAL & INTERNAL | THERAPY | EFFICACY | SAFETY | HIGH-RISK | PRIMARY HYPERCHOLESTEROLEMIA | GUIDELINES | CARDIOVASCULAR-DISEASE | EZETIMIBE | Proprotein Convertases - antagonists & inhibitors | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Coronary Disease - epidemiology | Male | Risk | Hypercholesterolemia - drug therapy | Contraindications | Musculoskeletal Pain - chemically induced | Dose-Response Relationship, Drug | Injections, Subcutaneous | Serine Endopeptidases - immunology | Cholesterol, LDL - blood | Female | Muscular Diseases - chemically induced | Syncope - chemically induced | Hip Fractures - chemically induced | Hypercholesterolemia - blood | Coronary Disease - chemically induced | Double-Blind Method | Cholesterol, LDL - drug effects | Anticholesteremic Agents - adverse effects | Proprotein Convertases - immunology | Coronary Disease - prevention & control | Hydroxymethylglutaryl-CoA Reductase Inhibitors - adverse effects | Antibodies, Monoclonal - administration & dosage | Anticholesteremic Agents - administration & dosage | Aged | Proprotein Convertase 9 | Clinical trials | Monoclonal antibodies | Low density lipoprotein | Patients | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2016, Volume 75, Issue 1, pp. 83 - 98.e4
Background Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, has demonstrated efficacy and safety in patients with moderate to severe plaque... 
Dermatology | pooled analysis | phase II studies | phase III studies | psoriasis | secukinumab | long-term safety | Phase III studies | Secukinumab | Long-term safety | Pooled analysis | Psoriasis | Phase II studies | CONTROLLED-TRIAL | CONFIDENCE-INTERVALS | FOLLOW-UP | RISK | long | DERMATOLOGY | LONGITUDINAL ASSESSMENT | CANDIDA-ALBICANS | REGISTRY PSOLAR | DISEASE | DOUBLE-BLIND | HOST-DEFENSE | term safety | Severity of Illness Index | Etanercept - adverse effects | Psoriasis - drug therapy | Etanercept - administration & dosage | Mental Disorders - chemically induced | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Infection - chemically induced | Randomized Controlled Trials as Topic | Clinical Trials, Phase III as Topic | Neoplasms - chemically induced | Interleukin-17 - antagonists & inhibitors | Time Factors | Antibodies, Monoclonal - administration & dosage | Adult | Female | Immunosuppressive Agents - adverse effects | Inflammatory Bowel Diseases - chemically induced | Cardiovascular Diseases - chemically induced | Neutropenia - chemically induced | Immunosuppressive Agents - administration & dosage | Clinical Trials, Phase II as Topic | Medical research | Care and treatment | Interleukins | Clinical trials | Monoclonal antibodies | Medicine, Experimental | Pharmaceutical industry | Consulting services | Index Medicus
Journal Article
by Baigent, Colin and Bhala, N and Emberson, J and Merhi, A and Abramson, S and Arber, N and Baron, J.A and Bombardier, C and Cannon, C and Farkouh, M.E and FitzGerald, G.A and Goss, P and Halls, H and Hawk, E and Hawkey, C and Hennekens, C and Hochberg, M and Holland, L.E and Kearney, P.M and Laine, L and Lanas, A and Lance, P and Laupacis, A and Oates, J and Patrono, C and Schnitzer, T.J and Solomon, S and Tugwell, P and Wilson, K and Wittes, J and Adelowo, O and Aisen, P and Al-Quorain, A and Altman, R and Bakris, G and Baumgartner, H and Bresee, C and Carducci, M and Chang, D.-M and Chou, C.-T and Clegg, D and Cudkowicz, M and Doody, L and Miedany, Y.El and Falandry, C and Farley, J and Ford, L and Garcia-Losa, M and Gonzalez-Ortiz, M and Haghighi, M and Hala, M and Iwama, T and Jajic, Z and Kerr, D and Kim, H.-S and Kohne, C and Koo, B.-K and Martin, B and Meinert, C and Muller, N and Myklebust, G and Neustadt, D and Omdal, R and Ozgocmen, S and Papas, A and Patrignani, P and Pelliccia, F and Roy, V and Schlegelmilch, I and Umar, A and Wahlstrom, O and Wollheim, F and Yocum, S and Zhang, X.Y and Hall, E and McGettigan, P and Midgley, R and Moore, R.A and Philipson, R and Curtis, S and Reicin, A and Bond, J and Moore, A and Essex, M and Fabule, J and Morrison, B and Tive, L and Bhala, N and Davies, K and Emberson, J and Halls, H and Holland, L.E and Kearney, P.M and Merhi, A and Patrono, C and Wilson, K and Yau, F and Coxib Traditional NSAID Trialists and Coxib and traditional NSAID Trialists' (CNT) Collaboration
Lancet, The, ISSN 0140-6736, 2013, Volume 382, Issue 9894, pp. 769 - 779
Journal Article
New England Journal of Medicine, ISSN 0028-4793, 12/2016, Volume 375, Issue 26, pp. 2519 - 2529
BACKGROUND The cardiovascular safety of celecoxib, as compared with nonselective nonsteroidal anti-inflammatory drugs (NSAIDs), remains uncertain. METHODS... 
MEDICINE, GENERAL & INTERNAL | PAIN | METAANALYSIS | OSTEOARTHRITIS | CLINICAL-TRIAL | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | Celecoxib - adverse effects | Naproxen - adverse effects | Ibuprofen - therapeutic use | Humans | Middle Aged | Male | Risk | Celecoxib - therapeutic use | Naproxen - therapeutic use | Cyclooxygenase 2 Inhibitors - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Arthritis - drug therapy | Cyclooxygenase 2 Inhibitors - therapeutic use | Intention to Treat Analysis | Kidney Diseases - chemically induced | Cardiovascular Diseases - mortality | Female | Aged | Cardiovascular Diseases - chemically induced | Ibuprofen - adverse effects | Gastrointestinal Diseases - chemically induced | Care and treatment | Safety and security measures | Naproxen | Ibuprofen | Dosage and administration | Arthritis | Celecoxib | Diagnosis | Cardiovascular diseases | Risk factors | Cardiovascular disease | Side effects | Nonsteroidal anti-inflammatory drugs | Pain management | Myocardial infarction | Fees & charges | Hemorrhage | Pain | Motivation | Analgesics | Safety | Drug dosages | Cerebral infarction | Statistical analysis | Anemia | Committees | FDA approval | Patients | Manuscripts | Nonsteroidal antiinflammatory drugs | Rheumatoid arthritis | Collaboration | Osteoarthritis | Pharmaceuticals | Index Medicus | Abridged Index Medicus
Journal Article